Protective actions of 5′-n-alkylated curcumins on living cells suffering from oxidative stress

Oyama, Yasuo; Masuda, Toshiya; Nakata, Mami; Chikahisa, Lumi; Yamazaki, Yuko; Miura, Kumiko; Okagawa, Makiko

doi:10.1016/s0014-2999(98)00635-9

Cited by 31 publications

(19 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each species of ginger contains unique compounds with structures similar to curcumin such as "yakuchinones" in A. oxyphylla (Chun et al, 1999), and cassumunin A and B from Z. cassumunar (Oyama et al, 1998) or different from curcumin such as paradol and gingerol from Z. officinale (Lee & Surh, 1998). The yellow pigment curcumin is the bioactive compound isolated from C. longa and has been extensively studied, therefore we used an ethanol extract of C. longa to compare the activity of extracts from other species.…”

Section: Discussionmentioning

confidence: 99%

Screening for Antitumor Activity of 11 Species of Indonesian Zingiberaceae Using Human MCF-7 and HT-29 Cancer Cells

Kirana

Record

McIntosh

et al. 2003

Pharmaceutical Biology

View full text Add to dashboard Cite

We have screened 11 important species of Zingiberaceae, used as spices and for medicinal purposes in Indonesia, for their antitumor activity using human HT-29 colon cancer and MCF-7 breast cancer cells. They were Amommum cardamomum, Curcuma aeruginosa, C. longa, C. mangga, C. xanthorrhiza, Kaempferia galanga, K. pandurata, K. rotunda, Z. aromaticum, Z. cassumunar, and Zingiber officinale. Ethanol extracts of eight species showed strong inhibitory effect on the growth of the cancer cells when evaluated using the colorimetric tetrazolium salt assay. Since curcumin, a yellow pigment isolated from C. longa, has shown its potential anticancer activity in vitro and in vivo studies and is currently undergone clinical trial in the US, we used an extract of C. longa as a comparison. Extracts of K. pandurata and Z. aromaticum had very strong inhibitory activity against the two cell lines similar to those of C. longa. However, curcumin was not detectable in the extracts of those two plants. The ethanol extracts of the active species had less effect on the growth of a non-transformed human skin fibroblast cell line (SF 3169). Microscopic examination of cancer cells exposed to extracts of active species showed a characteristic morphology of apoptosis. Further study on Z. aromaticum and K. pandurata, including identification of bioactive compounds and elucidation of mechanism(s) likely to be operating, has been carried out.

show abstract

Section: Discussionmentioning

confidence: 99%

Screening for Antitumor Activity of 11 Species of Indonesian Zingiberaceae Using Human MCF-7 and HT-29 Cancer Cells

Kirana

Record

McIntosh

et al. 2003

Pharmaceutical Biology

View full text Add to dashboard Cite

show abstract

“…We have already reported that curcumin induces apoptosis in human breast carcinoma cells (20). In contrast, curcumin has been found to protect normal cells from stressinduced apoptosis (24). Inhibition of both proliferation and apoptosis of T lymphocytes by this curry pigment led us to conclude that the inhibition of cell proliferation by curcumin was not always associated with programmed cell death (25).…”

mentioning

confidence: 88%

Curcumin Selectively Induces Apoptosis in Deregulated Cyclin D1-expressed Cells at G2 Phase of Cell Cycle in a p53-dependent Manner

Choudhuri

Pal

Das

et al. 2005

Journal of Biological Chemistry

289

226

View full text Add to dashboard Cite

Curcumin (diferuloylmethane) is known to induce apoptosis in tumor cells. In asynchronous cultures, with time-lapse video-micrography in combination with quantitative fluorescence microscopy, we have demonstrated that curcumin induces apoptosis at G 2 phase of cell cycle in deregulated cyclin D1-expressed mammary epithelial carcinoma cells, leaving its normal counterpart unaffected. In our search toward delineating the molecular mechanisms behind such differential activities of curcumin, we found that it selectively increases p53 expression at G 2 phase of carcinoma cells and releases cytochrome c from mitochondria, which is an essential requirement for apoptosis. Further experiments using p53-null as well as dominant-negative and wildtype p53-transfected cells have established that curcumin induces apoptosis in carcinoma cells via a p53-dependent pathway. On the other hand, curcumin reversibly inhibits normal mammary epithelial cell cycle progression by down-regulating cyclin D1 expression and blocking its association with Cdk4/Cdk6 as well as by inhibiting phosphorylation and inactivation of retinoblastoma protein. In addition, curcumin significantly up-regulates cell cycle inhibitory protein (p21Waf-1) in normal cells and arrests them in G 0 phase of cell cycle. Therefore, these cells escape from curcumin-induced apoptosis at G 2 phase. Interestingly, these processes remain unaffected by curcumin in carcinoma cells where cyclin D1 expression is high. Similarly, in ectopically overexpressed system, curcumin cannot down-regulate cyclin D1 and thus block cell cycle progression. Hence, these cells progress into G 2 phase and undergo apoptosis. These observations together suggest that curcumin may have a possible therapeutic potential in breast cancer patients.

show abstract

“…Therefore, Axl has been receiving increased attention as a potent therapeutic target for cancer treatment. Curcumin, a polyphenolic compound extracted from Curcuma longa, is a well-known natural product with antioxidant, anti-inflammatory and anticancer activities (26,27). Recent clinical investigations demonstrated that curcumin has not only chemo-preventive, but also therapeutic potential in many types of cancer.…”

Section: Introductionmentioning

confidence: 99%

Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells

Kim

Baek

Lee

2015

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Lung cancer is still in the first place in terms of both incidence and mortality. In the present study, we demonstrated the effect of curcumin, a phytochemical of the plant Curcuma longa, on expression and activation of Axl receptor tyrosine kinase (RTK) which plays an important role in cell survival, proliferation and anti-apoptosis. Curcumin treatment of nonsmall cell lung cancer (NSCLC) A549 and H460 cells, was found to decrease Axl protein as well as mRNA levels in a dose-and time-dependent manner. Axl promoter activity was also reduced by curcumin, indicating that curcumin downregulates Axl expression at the transcriptional level. Moreover, Axl phosphorylation in response to binding of its ligand, Gas6, was abrogated by curcumin, suggesting the inhibitory effect of curcumin on Gas6-induced Axl activation. We next found cytotoxic effect of cucumin on both the parental A549 and H460 cells, and their variants which are resistant to cisplatin (A549/CisR and H460/CisR) and paclitaxel (A549/TR and H460/TR). Exposure of these cells to curcumin resulted in dose-dependent decline of cell viability and clonogenic ability. It is further observed that the anti-proliferative effect of curcumin on A549 cells overexpressing Axl protein was reduced, while that on H460 cells transfected Axl specific siRNA was augmented, confirming that curcumin inhibits cell proliferation via downregulation of Axl expression. In addition, curcumin was found to cause the induction of p21, a cyclin-dependent kinase inhibitor, and reduction of X-linked inhibitor of apoptosis protein (XIAP), an anti-apoptotic molecule, in parental H460 cells as well as chemoresistant cells, H460/CisR and H460/TR. Taken together, our data imply that Axl RTK is a novel target of curcumin through which it exerts anti-proliferative effect in both parental and chemoresistant NSCLC cells. IntroductionWorldwide, lung cancer is the most frequently diagnosed cancer and the leading cause of cancer deaths (1). Approximately 85-90% of lung cancer is non-small cell lung cancer (NSCLC) which is characterized by relatively low growth rate and poor responsiveness upon chemotherapy, compared to small cell lung cancer (SCLC) (2). Although platinum or taxol-based chemotherapy has been the standard treatment for NSCLC patients, the intrinsic and acquired resistances to these drugs are the major obstacles to achieve the successful long-term outcomes. To overcome the resistance, the second line or combination chemotherapy regimens have been used (3-5), but the overall survival benefits of various chemotherapies in NSCLC is not yet satisfactory.The large receptor tyrosine kinase (RTK) family in the human genome contains 58 RTKs and is divided into 20 subfamilies. One of the subfamilies is TAM family composed of three RTK members which are Tyro3 (also referred to Brt, Dtk, Rse, Sky or Tif ), Axl (also referred to Ark, Tyro7 or Ufo) and Mer (also referred to Eyk, Nyk or Tyro12) (6-9). Each of them has similar structural features, which are extracellular domains, two immunoglo...

show abstract

Protective actions of 5′-n-alkylated curcumins on living cells suffering from oxidative stress

Cited by 31 publications

References 12 publications

Screening for Antitumor Activity of 11 Species of Indonesian Zingiberaceae Using Human MCF-7 and HT-29 Cancer Cells

Screening for Antitumor Activity of 11 Species of Indonesian Zingiberaceae Using Human MCF-7 and HT-29 Cancer Cells

Curcumin Selectively Induces Apoptosis in Deregulated Cyclin D1-expressed Cells at G2 Phase of Cell Cycle in a p53-dependent Manner

Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells

Contact Info

Product

Resources

About